| Literature DB >> 35070854 |
José da Costa Pimenta1, Maria José Saavedra1,2,3, Gabriela Jorge da Silva4, Mário Cotovio1,3.
Abstract
BACKGROUND: Many emergent pathogenic agents are cross-transmitted from animals to humans. Horses are considered as potential reservoirs of commensal, zoonotic, and multidrug-resistant bacteria. Equine bites could lead to infections caused by these agents, considering equine species as a public health concern. The more it is known about the equine oral microbiota the best secondary problems created by their commensal flora can be controlled. There are very few reports of Serratia rubidaea, a zoonotic and opportunistic bacterium, both in human and veterinary medicine. AIM: This study aimed to evaluate the Gram-negative microbiota of healthy equine oral cavities and their antimicrobial susceptibility.Entities:
Keywords: Antimicrobial Resistance; Horse; Oral microbiota; Serratia
Mesh:
Substances:
Year: 2021 PMID: 35070854 PMCID: PMC8770173 DOI: 10.5455/OVJ.2021.v11.i4.9
Source DB: PubMed Journal: Open Vet J ISSN: 2218-6050
Fig. 1.Percentage of resistance to antimicrobial classes tested.
Fig. 2.Percentage of resistance of each antimicrobial. (AML10): amoxicillin; (AMC30): amoxicillin/clavulanate; (TIC75): ticarcillin; (TIM85): ticarcillin-clavulanic acid; (PRL100): piperacillin; (TZP110): piperacillin-tazobactam; (ATM30): aztreonam; (KF30): cephalothin; (IMP10): imipenem; (FOS50): Fosfomycin; (FOX30): cefoxitin; (CAZ30): ceftazidime; (CTX30): cefotaxime; (CRO30): ceftriaxone; (CFP30): cefoperazone; (NA30): nalidixic acid; (CIP5): ciprofloxacin; (MEM10): meropenem; (K30): kanamycin; (TOB10): tobramycin; (CN10): gentamicin; (AK30): amikacin; (SXT25): trimethoprim-sulfamethoxazole; (C30): chloramphenicol; (E15): erythromycin; (TE30): tetracycline; (ETP10): ertapenem.
Resistance rates toward AM classes tested. Only bacterial species with at least 2 tested isolates are shown.
| Gram-negative | β-lactamics | Aminogly-cosids | Quinolo-nes | Macroli-des | Sulfonami-des | Tetracyc-lins | Phenic-ols | Phos-phomycin | |
|---|---|---|---|---|---|---|---|---|---|
|
| ( | 37.5% | 55.4% | 17.9% | 92.9% | 7.1% | 0% a | 14.3% | 14.3% |
|
| ( | 57.8% | 93.8% | 18.8% | 100% | 25% | 25% a | 25% | 0% |
|
| ( | 97.6% | 75% | 83.3% | 100% | 66.7% | 66.7% c | 66.7% | 66.7% |
|
| ( | 65.6% | 87.5% | 25% | 100% | 0% | 100% c | 0% | 0% |
|
| ( | 75% | 25% | 25% | 100% | 0% | 0% a | 50% | 100% |
0%–25% resistance.
26%–50% resistance.
51%–100% resistance.